Trial Profile

A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ralimetinib (Primary) ; Midazolam; Tamoxifen
Indications Cancer; Lymphoma
Focus Adverse reactions; First in man
Sponsors Eli Lilly and Company

Most Recent Events

12 Mar 2016 Results (n=40) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
18 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
17 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com